Related references
Note: Only part of the references are listed.Rheumatoid Arthritis in the View of Osteoimmunology
Melanie Aureal et al.
BIOMOLECULES (2021)
A MULTICENTER RANDOMIZED STUDY IN RHEUMATOID ARTHRITIS TO COMPARE IGURATIMOD, METHOTREXATE, OR COMBINATION: 52 WEEK EFFICACY AND SAFETY RESULTS OF THE SMILE TRIAL
F. Du et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs
Chao-Jun Hu et al.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2021)
Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient-Companion Diagnostics
Richard Thomas Meehan et al.
DIAGNOSTICS (2021)
Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study
Rong Mu et al.
LANCET REGIONAL HEALTH-WESTERN PACIFIC (2021)
Molecular mechanisms and clinical application of Iguratimod: A review
Huihui Jiang et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
Sisi Xie et al.
FRONTIERS IN PHARMACOLOGY (2020)
Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study
Tsuneyo Mimori et al.
MODERN RHEUMATOLOGY (2019)
Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients
Koichiro Ishikawa et al.
MODERN RHEUMATOLOGY (2019)
The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab
Kosuke Ebina et al.
MODERN RHEUMATOLOGY (2019)
The epidemiology of established rheumatoid arthritis
Teresa Oton et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2019)
Role of Semaphorins in Immunopathologies and Rheumatic Diseases
Samuel Garcia
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers
Feng Xiao et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study
Ayaka Yoshikawa et al.
MODERN RHEUMATOLOGY (2018)
Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan
Tsuneyo Mimori et al.
MODERN RHEUMATOLOGY (2017)
Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014
Theresa M. Hunter et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis
Xuetong Wang et al.
CLINICAL RHEUMATOLOGY (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Iguratimod in combination with methotrexate in active rheumatoid arthritis Therapeutic effects
Z. Xia et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2016)
Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
Jiangtao Li et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial
Naoki Ishiguro et al.
MODERN RHEUMATOLOGY (2013)
T-614 alters the production of matrix metalloproteinases (MMP-1 and MMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro
Fang Du et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2012)
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Daniel Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Multicenter, Randomized, Double-Blind, Controlled Trial of Treatment of Active Rheumatoid Arthritis With T-614 Compared With Methotrexate
Liang-jing Lu et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Inflammatory Cytokines and Hypoxia Contribute to 18F-FDG Uptake by Cells Involved in Pannus Formation in Rheumatoid Arthritis
Tamiko Matsui et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Share Paper
